Ataxia is a type of movement disorder characterized by lack of muscle control or coordination of voluntary movements. Some of the symptoms observed in the patients with ataxia are poor coordination, change in speech, difficulty in swallowing, and unsteady walk. The disease causes include head injury; stroke; autoimmune diseases, such as sarcoidosis and multiple sclerosis; paraneoplastic syndromes; and viral infections. The disease is also found in patients with vitamin E, B12, or thiamine deficiency. Ataxia can be diagnosed by lumbar puncture; imaging studies, such as computed tomography and magnetic resonance imaging; and genetic testing. Catabasis Pharmaceuticals Inc. is in the process of developing CAT4001 as a NFE2 related factor 2 stimulant for the treatment of ataxia. Chondrial Therapeutics Inc. is in the process of developing CTI-1601 as a frataxin protein replacement for the treatment of ataxia. Some of the companies involved in ataxia pipeline are Cardero Therapeutics Inc., Reata Pharmaceuticals Inc., and Voyager Therapeutics among others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.